Abstract
The existence of specific angiogenesis inhibitors was first postulated by Judah Folkman in 1971. The term "antiangiogenesis" was introduced to describe treatments designed to prevent the induction of new blood vessels and perhaps reduce the number of those already present. Several approaches inhibit tumor angiogenesis and more than 60 antiangiogenic compounds have been clinically evaluated. Because tumorassociated angiogenesis takes place in a physiological context, its inhibition should not induce resistance and should potentiate the oncostatic effect, because each neovessel supplies hundreds of tumor cells. Inhibitors may be synthetic or semi-synthetic agents, endogenous inhibitors, or biological antagonists of the angiogenic cascade. Several direct and indirect vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) inhibitor strategies are under clinical investigation for treatment of solid tumors and hematological malignancies. Approaches to disrupt the VEGF/VEGFR signalling pathways range from small-molecule ATP competitive VEGFR inhibitors to biological agents such as soluble receptors, anti-VEGF and anti-VEGFR antibodies, small molecule inhibitors, and VEGF transcription inhibitors. This review summarizes the literature on the use of these molecules in the treatment of hematological malignancies.
Keywords: Angiogenesis, antiangiogenesis, haematological malignancies, tumor growth, VEGF, VEGFR
Current Cancer Drug Targets
Title: Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies
Volume: 5 Issue: 8
Author(s): Domenico Ribatti and Angelo Vacca
Affiliation:
Keywords: Angiogenesis, antiangiogenesis, haematological malignancies, tumor growth, VEGF, VEGFR
Abstract: The existence of specific angiogenesis inhibitors was first postulated by Judah Folkman in 1971. The term "antiangiogenesis" was introduced to describe treatments designed to prevent the induction of new blood vessels and perhaps reduce the number of those already present. Several approaches inhibit tumor angiogenesis and more than 60 antiangiogenic compounds have been clinically evaluated. Because tumorassociated angiogenesis takes place in a physiological context, its inhibition should not induce resistance and should potentiate the oncostatic effect, because each neovessel supplies hundreds of tumor cells. Inhibitors may be synthetic or semi-synthetic agents, endogenous inhibitors, or biological antagonists of the angiogenic cascade. Several direct and indirect vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) inhibitor strategies are under clinical investigation for treatment of solid tumors and hematological malignancies. Approaches to disrupt the VEGF/VEGFR signalling pathways range from small-molecule ATP competitive VEGFR inhibitors to biological agents such as soluble receptors, anti-VEGF and anti-VEGFR antibodies, small molecule inhibitors, and VEGF transcription inhibitors. This review summarizes the literature on the use of these molecules in the treatment of hematological malignancies.
Export Options
About this article
Cite this article as:
Ribatti Domenico and Vacca Angelo, Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies, Current Cancer Drug Targets 2005; 5 (8) . https://dx.doi.org/10.2174/156800905774932806
DOI https://dx.doi.org/10.2174/156800905774932806 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets MicroRNAs as Regulators in Normal Hematopoietic and Leukemia Stem Cells: Current Concepts and Clinical Implications
Current Molecular Medicine Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes
Current Drug Targets Nanotechnology and Radiopharmaceuticals: Diagnostic and Therapeutic Approaches
Current Drug Delivery Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Stromal Derived Growth Factor-1alpha as a Beacon for Stem Cell Homing in Development and Injury
Current Neurovascular Research The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Non-Transferrin Bound Iron - Determination in Biological Material and Clinical Implications
Current Pharmaceutical Analysis Pharmacological Interventions for the Prevention and Treatment of Kidney Injury Induced by Radiotherapy: Molecular Mechanisms and Clinical Perspectives
Current Molecular Pharmacology Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives
Current Molecular Medicine Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Molecular Targets and Targeted Therapies for Malignant Mesothelioma
Current Medicinal Chemistry Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews Chronic Granulomatous Disease in Childhood
Current Pediatric Reviews State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry